Cefepime is one of the workhorse antibiotics of modern hospital medicine — reached for constantly to treat pneumonia, UTIs, meningitis, and the dangerous fever-and-low-white-blood-cell emergency called febrile neutropenia. A new, large analysis finds it’s linked to a meaningfully higher risk of death than similar antibiotics. What’s less settled is why — and even the experts commenting on the same data don’t fully agree.
Key Takeaways
- A new meta-analysis of 110 randomized trials and more than 22,000 patients found cefepime was associated with higher all-cause mortality than other beta-lactam antibiotics, with a 94.4% statistical probability of a real difference.
- Researchers estimated a “number needed to harm” of 227 across all trials — meaning roughly one additional death for every 227 patients treated with cefepime instead of a comparable antibiotic — dropping to 111 when limited to peer-reviewed published trials specifically.
- The association was strongest in adults and in patients being treated for febrile neutropenia, and wasn’t clearly present in children.
- Researchers aren’t recommending doctors stop using cefepime; they’re calling for more research and clearer dosing guidance, and a competing expert view argues the real issue is dosing, not the drug itself.
What the Researchers Found
Led by Dr. Zahra N. Sohani of Hôpital Maisonneuve-Rosemont in Montreal, the team pooled data from 110 randomized clinical trials comparing cefepime against other beta-lactam antibiotics — a drug class that includes penicillins, cephalosporins, and carbapenems. Across all trials, 778 of 11,726 patients (6.6%) who received cefepime died within about 30 days, compared to 6.2% of patients on a comparison antibiotic. Using Bayesian statistical methods, the researchers calculated a 94.4% probability that this reflects a real difference in mortality risk tied to cefepime specifically — a figure that rose to 98.6% when the analysis was narrowed to the 73 trials that had gone through full peer review. In head-to-head comparisons, cefepime was specifically linked to higher mortality than ceftazidime and carbapenems, two other commonly used antibiotic options. Notably, this isn’t a brand-new concern — a 2007 meta-analysis first raised a similar mortality signal, which this new, much larger analysis was partly designed to re-examine with better statistical methods.
Why Cefepime Is Still So Widely Used
It’s worth understanding why doctors reach for this drug so often despite a mortality question that’s now been raised twice. Cefepime has a genuine clinical advantage: it remains effective against a class of resistant bacteria (producers of AmpC beta-lactamase enzymes) that can defeat many other antibiotics, making it a valuable option precisely when other choices are failing. That clinical value is part of why researchers are urging caution and more study rather than recommending doctors abandon it outright.
Two Competing Explanations
The study’s authors point to a specific, plausible mechanism: cefepime has a relatively narrow therapeutic window, meaning the gap between an effective dose and a harmful one is smaller than with many other antibiotics. Too little cefepime risks under-treating a dangerous infection; too much raises the risk of neurotoxicity — cefepime is known to cross the blood-brain barrier and can trigger confusion, reduced consciousness, myoclonus, and seizures, particularly in patients with kidney problems, where the drug can build up to dangerous levels. Separate research has found neurotoxicity affects up to 15% of ICU patients on cefepime, with kidney dysfunction as the leading risk factor.